Location Directory

Clinical trials in Birmingham, Alabama

This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9512

Shown on this page

Current sort

Institutions in Birmingham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Alabama at Birmingham

Live official records

Open in full search

Conditions: Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities, Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Surgical Procedure; Radiation · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 67
States / cities: Birmingham, Alabama • Anaheim, California • Antioch, California + 48 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 39
States / cities: Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more

Conditions: Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism, Arterial Embolism
Interventions: Coronary and peripheral stents, Pacing catheters, Vascular plugs, Measurement and imaging (FFR and OCT), Peripheral dilatation catheters, Coronary dilatation catheters, Coronary and peripheral guidewires, Vessel closure/compression devices, Vascular access introducers; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 3,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 7
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 4 more

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions: Omecamtiv Mecarbil (OM), Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 88
States / cities: Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 77 more

Conditions: Fabry Disease
Interventions: Venglustat (GZ402671), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more

Conditions: Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Interventions: ELA026; Drug
Lead sponsor: Electra Therapeutics Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more

Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Interventions: BL-M07D1; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 19 more

Conditions: Cutaneous Lichen Planus
Interventions: Placebo, GIA632; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 15
States / cities: Birmingham, Alabama • Fountain Valley, California • Miami, Florida + 12 more

Conditions: Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 63 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Malignant Glioma
Interventions: Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 111
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more

Conditions: Diet, Healthy, Pregnancy
Interventions: Meal Delivery; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Clinical trials in Birmingham, Alabama

Filter and sort this location

Institutions in Birmingham

Live official records

Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Abbott Vascular Medical Device Registry

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Hearty Meals for Mom- Pilot Study of Meal Delivery for Cardiometabolic Health During Pregnancy